Scienture Holdings Inc (SCNX) Börsenkurse

Form DEF 14C - Other definitive information statements

Form PRE 14C - Other preliminary information statements

Form D - Notice of Exempt Offering of Securities

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the “Company”) (NASDAQ: SCNX), a specialty pharma company with a novel pipeline of brand products, is pleased to announce...

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE, LLC (“the “Company”), a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), focused on developing and...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement

Scienture Holdings to Receive Funding of Up to $12 Million From Private Placement of 10% Secured Convertible Debentures and Up to $50 Million from Equity Line of Credit Tampa, FL, Nov. 26, 2024...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

TRxADE Health, Inc. today announced that it changed its name and ticker symbol to “Scienture Holdings, Inc.” and “SCNX”, respectively, and that the business will continue as a Nasdaq-listed...